Bexotegrast, is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis (IPF). Bexotegrast has been administered to over 600 study participants to date, including healthy volunteers and patients, with no drug-related severe or serious adverse events reported to date.
Favorite AI Stock, Hedge Funds Win At The Expense Of Asset Allocators – Investors Discover Massive National Debt
To gain an edge, this is what you need to know today.
